Vyepti Injection
Product Images NDC 67386-130

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Vyepti (NDC 67386-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lundbeck Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Change From Baseline In Monthly Migraine Days In Study 1 (Vyepti 1)

FDA Label Image

Figure 2. Distribution Of Change From Baseline In Mean Monthly Migraine Days Over Months 1 To 3 By Treatment Group In Study 1 (Vyepti 2)

This appears to be a table that shows the percentage of patients who experience fewer migraine days per month on placebo vs. two different doses of VYEPTI medication (100 mg quarterly and 300 mg quarterly). The table also displays the number of patients in each group (222 for placebo, and 221 and 222 for the two VYEPTI doses). There are also percentages displayed on the y-axis ranging from 10-30%, and a chart underneath that shows a decrease in migraine days over the course of the study.*

FDA Label Image

Figure 3. Percentage Of Patients With A Migraine From Day -1 (day Prior To Infusion) To Day 7 In Study 1 (Vyepti 3)

This is a chart depicting the percentage of patients with a migraine before and after infusion of different treatments. The treatments mentioned are VYEPTI 300 mg, VYEPTI 100 mg, and Placebo. The chart seems to indicate that VYEPTI 300 mg has a lower percentage of patients with a migraine compared to 100 mg and Placebo. The horizontal axis indicates the number of days post-infusion. Nonetheless, no information is provided regarding the overall efficacy of the treatments or the sample size used to generate these results.*

FDA Label Image

Figure 4. Change From Baseline In Monthly Migraine Days In Study 2 (Vyepti 4)

FDA Label Image

Figure 5. Distribution Of Change From Baseline In Mean Monthly Migraine Days Over Months 1-3 By Treatment Group In Study 2 (Vyepti 5)

This seems to be a chart showing the percentage of patients experiencing a reduction in migraine days per month while taking the medication VYEPTI 100mg or 300mg quarterly, compared to those taking a placebo. The chart also indicates that there were fewer migraine days in those taking VYEPTI, but no change or an increase in migraine days in some patients. The lower section of the chart includes dates and numbers that are difficult to interpret.*

FDA Label Image

Figure 6. Percentage Of Patients With A Migraine From Day -1 (day Prior To Infusion) To Day 7 In Study 2 (Vyepti 6)

This is a graph that shows the percentage of patients with a migraine (measured with standard error) on different days after infusion with either VYEPTI 300 mg, VYEPTI 100 mg or a placebo. The days range from 3 to 4.*

FDA Label Image

Lundbeck Logo 1 (Vyepti 7)

FDA Label Image

Lundbeck (Vyepti 8)

FDA Label Image

Ndc 67386-130-51 Vyeptitm (vye Ep' Tee) (eptinezumab-jjmr) Injection, For Intravenous Use 100 mg/ml Injection, For Intravenous Use 100 mg/ml (Vyepti 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.